Last reviewed · How we verify
TdcP-IPV vaccine
The TdcP-IPV vaccine works by stimulating an immune response to protect against certain diseases.
The TdcP-IPV vaccine works by stimulating an immune response to protect against certain diseases. Used for Diphtheria, tetanus, and poliomyelitis prevention.
At a glance
| Generic name | TdcP-IPV vaccine |
|---|---|
| Also known as | ADACEL POLIO |
| Sponsor | Sanofi |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
It achieves this by introducing inactivated poliovirus and tetanus toxoid antigens to the body, which triggers the production of antibodies and immune cells to fight these pathogens. This process helps build immunity and prevent future infections.
Approved indications
- Diphtheria, tetanus, and poliomyelitis prevention
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis (PHASE2)
- Immunogenicity and Safety of Adacel Polio Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TdcP-IPV vaccine CI brief — competitive landscape report
- TdcP-IPV vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI